RJA
AMRX icon

Raymond James & Associates’s Amneal Pharmaceuticals AMRX Stock Holding History

Raymond James & Associates’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.34M Sell
161,380
-745
-0.5% -$5.83K ﹤0.01% 2489
2024
Q2 		$1.03M Sell
162,125
-2,963
-2% -$18.8K ﹤0.01% 2608
2024
Q1 		$1M Buy
165,088
+3,451
+2% +$19.5K ﹤0.01% 2591
2023
Q4 		$981K Sell
161,637
-19,750
-11% -$88K ﹤0.01% 2531
2023
Q3 		$765K Buy
181,387
+20,000
+12% +$74.6K ﹤0.01% 2627
2023
Q2 		$500K Hold
161,387
– – ﹤0.01% 2944
2023
Q1 		$224K Hold
161,387
– – ﹤0.01% 3430
2022
Q4 		$321K Hold
161,387
– – ﹤0.01% 3174
2022
Q3 		$326K Sell
161,387
-4,586
-3% -$12.9K ﹤0.01% 3129
2022
Q2 		$528K Sell
165,973
-2,000
-1% -$7.25K ﹤0.01% 2884
2022
Q1 		$700K Sell
167,973
-4,500
-3% -$19.9K ﹤0.01% 2847
2021
Q4 		$826K Sell
172,473
-2,579
-1% -$12.9K ﹤0.01% 2752
2021
Q3 		$935K Buy
175,052
+2,000
+1% +$10.1K ﹤0.01% 2623
2021
Q2 		$886K Buy
173,052
+3,000
+2% +$17.1K ﹤0.01% 2673
2021
Q1 		$1.14M Sell
170,052
-3,967
-2% -$22K ﹤0.01% 2413
2020
Q4 		$795K Sell
174,019
-210
-0.1% -$931 ﹤0.01% 2489
2020
Q3 		$676K Buy
174,229
+6,465
+4% +$27.6K ﹤0.01% 2431
2020
Q2 		$799K Buy
167,764
+250
+0.1% +$1.03K ﹤0.01% 2310
2020
Q1 		$583K Buy
167,514
+37,000
+28% +$157K ﹤0.01% 2313
2019
Q4 		$629K Buy
130,514
+32,880
+34% +$114K ﹤0.01% 2564
2019
Q3 		$283K Buy
97,634
+53,941
+123% +$188K ﹤0.01% 3045
2019
Q2 		$313K Buy
43,693
+5,799
+15% +$59.3K ﹤0.01% 2987
2019
Q1 		$537K Sell
37,894
-9,041
-19% -$119K ﹤0.01% 2602
2018
Q4 		$635K Sell
46,935
-11,860
-20% -$214K ﹤0.01% 2383
2018
Q3 		$1.3M Buy
58,795
+14,834
+34% +$312K ﹤0.01% 2074
2018
Q2 		$721K Buy
+43,961
New +$771K ﹤0.01% 2423

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's AMRX Position: Q3 2024 in Review

Raymond James & Associates reduced its Amneal Pharmaceuticals (AMRX) stake by 0.46% in Q3 2024, selling an estimated $5.83K and leaving 161,380 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

Raymond James & Associates first reported a position in AMRX in Q2 2018 and has held it in 26 quarters since. 182 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

  • Raymond James & Associates held 161,380 shares of Amneal Pharmaceuticals worth $1.34M as of Q3 2024.
  • Raymond James & Associates sold 745 Amneal Pharmaceuticals shares in Q3 2024, an estimated $5.83K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2489 holding.
  • Raymond James & Associates first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 26 quarters since.
  • 182 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.